Publications, Presentations and Posters

17 – 21 September 2021

ESMO Congress 2021

– virtual –

A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with
avelumab in patients with treatment naïve metastatic Merkel cell carcinoma the MERKLIN 1 study

Poster

EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced
mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding

Poster

DONIMI study – Personalized combinations of neoadjuvant Domatinostat, Nivolumab and Ipilimumab in macroscopic stage III melanoma based on the IFN-gamma signature

Presentation

8 – 11 September 2021

31. Deutschen Hautkrebskongress

– hybrid –

A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment-naïve metastatic Merkel cell carcinoma – the MERKLIN 1 study

Poster

Presentation

A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study

Poster

Presentation

4 – 8 June 2021

ASCO Annual Meeting

– virtual –

Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy

Poster

Presentation

15 – 17 April 2021

10th World Congress of Melanoma and 17th EADO Congress

– virtual –

Efficacy and safety of domatinostat in combination with avelumab in advanced unresectable/metastatic Merkel Cell Carcinoma patients progressing on anti-PD-(L)1 therapy – MERKLIN 2 study

Poster

28 September 2020

Journal of Investigative Dermatology

The HDAC Inhibitor Domatinostat Promotes Cell Cycle Arrest, Induces Apoptosis and Increases Immunogenicity of Merkel Cell Carcinoma Cells

Lina Song, Anne Catherine Bretz, Jan Gravemeyer, Ivelina Spassova, Shakhlo Muminova, Thilo Gambichler, Ashwin Sriram, Soldano Ferrone, Jürgen C. Becker

doi: 10.1016/j.jid.2020.08.023

Publication

28 September 2020

Research Outreach, Health & Medicine

A New Weapon to Boost Cancer Immunotherapy

Svetlana Hamm Ph.D

Publication

17 – 21 September 2020

ESMO Congress 2020

– virtual –

A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study

Poster

8 November 2019

Journal for ImmunoTherapy of Cancer

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, Tobias Dreker, René Bartz, Frank Hermann, Astrid Ammendola, Tanja Wulff and Svetlana Hamm

Journal for ImmunoTherapy of Cancer; 2019 Nov 8;7(1):294.; doi: 10.1186/s40425-019-0745-3

Publication

21 – 22 October 2019

1st International Symposium on Merkel Cell Carcinoma

Tampa, Florida, USA

Preclinical rationale and clinical design for the combination of domatinostat with avelumab in Merkel Cell Carcinoma patients: the MERKLIN 1 and MERKLIN 2 studies

Poster

27 September – 1 October 2019

ESMO Congress 2019

Barcelona, Spain

Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma

Poster

EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal Cancers

Poster

29 March – 3 April 2019

AACR 2019

Atlanta, Georgia, USA

Domatinostat increases apoptosis, G2M cell cycle arrest and immunogenicity of Merkel cell carcinoma

Poster

Tumor abscopal responses induced by the TLR9 agonist, SD-101, are strongly potentiated by a HDAC class I inhibitor, Domatinostat

Poster

29 November – 1 December 2018

Melanoma Bridge 2018

Naples, Italy

Phase Ib cohort 1 data of class I HDAC inhibitor 4SC-202 (domatinostat) in combination with pembrolizumab in advanced cutaneous melanoma patients refractory or non-responding to prior anti-PD1 therapy

Presentation

28 – 29 November 2018

Immunotherapy Bridge 2018

Naples, Italy

Domatinostat’s impact on tumor immunophenotype and response to PD-(L)1 and LAG-3 blockade in pre-clinical models

Presentation

22 October 2018

European Journal of Haematology

Phase I Study of Domatinostat (4SC‐202), a class I Histone Deacetylase Inhibitor in Patients with Advanced Hematological Malignancies

Bastian von Tresckow, Cyrus Sayehli, Walter E. Aulitzky, Maria‐Elisabeth Goebeler, Matthias Schwab, Eunice Braz, Babett Krauss, Rolf Krauss, Frank Hermann, René Bartz, Andreas Engert

European Journal of Haematology, 2018 Oct 22; doi: 10.1111/ejh.13188

Publication

19 September – 22 September 2018

SIC Annual Meeting 2018

Milan, Italy

4SC-202 (domatinostat), a novel histone deacetylase inhibitor, improves chemotherapy efficacy and overcomes drug resistance in pancreatic cancer models

Poster

05 July – 06 July 2018
Cancer Epigenetics Therapies Conference
Naples, Italy
Domatinostat (4SC-202) as a core immune-modulatory combination partner for immunotherapy

Presentation

14 April – 18 April 2018
AACR 2018
Chicago, Illinois, US
4SC-202 primes tumor microenvironment for treatment with cancer immunotherapy

Poster

19 March – 21 March 2018
ITOC5 Conference 2018
Berlin, Germany
4SC-202 increases CTLs in tumor microenvironment and primes tumors for checkpoint therapy.

Poster

05 March – 07 March 2018
TAT 2018 – Targeted Anticancer Therapies
Paris, France
4SC-202 plus Anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma

Presentation

30 November – 02 Dezember 2017
Melanoma Bridge
Naples, Italy
4SC-202 plus Anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma

Presentation

29 – 30 November 2017
Immunotherapy Bridge
Naples, Italy
4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD-1/PD-L1 therapy

Presentation

12 – 13 October 2017
3rd Annual Epigenetics Discovery Meeting
London, United Kingdom
Modulation of the tumor microenvironment by epigenetic intervention

Presentation

27 – 28 September 2017
11th Annual Next-Generation Histone Deacetylase Inhibitors
Boston, MA, USA
Epigenetic Priming with New HDAC Class I Inhibitor 4SC-202 Sensitizes Tumor for Anti-PD-1/PD-L1 Therapy

Presentation

21 – 23 September 2017
27. Deutscher Hautkrebskongress, ADO-Jahrestagung
Mainz, Germany
4SC-202 + Pembrolizumab: “SENSITIZE” the tumor to overcome PD-1 refractoriness and increase efficacy of checkpoint inhibition in patients with advanced melanoma

Poster

8 – 12 September
ESMO 2017 Congress
Madrid, Spain
4SC-202 plus Anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma

Poster

1 – 5 April 2017
AACR Annual Meeting 2017
Washington, D.C., USA
4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD-1/PD-L1 therapy
PosterCombination of 4SC-202 and IFN-γ restores mature APC phenotype in AML cells
Poster
27 March 2017
Nucleic Acids Research

Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.

Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus HU, Najafova Z, Kari V, Kohlhof H, Hessmann E, Johnsen SA.

Nucleic Acids Res. 2017 Mar 27. doi: 10.1093/nar/gkx212.

Publication

December 2016
Targeted Oncology
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma CellLines.

Pinkerneil M, Hoffmann MJ, Kohlhof H, Schulz WA, Niegisch G.

Target Oncol. 2016 Dec;11(6):783-798.

Publication

30 November – 2 December 2016
4th Max Planck Freiburg Epigenetics Meeting
Freiburg, Germany
4SC-202 induces differentiation of AML cells by upregulating promoter histone acetylation

Poster

29 November – 2 December 2016
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Munich, Germany
4SC-202: Epigenetic modulator and potential combination partner for checkpoint inhibitors

Poster

8 September 2016
2nd Annual Epigenetics Discovery Congress
London, United Kingdom
Regulation of tumor microenvironment by the HDAC/LSD1 inhibitor 4SC-202

Presentation

16 June 2016
World Preclinical Congress – Cancer Immonotherapy and Combinations Congress
Boston, USA
Epigenetic therapeutics for combination with cancer immunotherapy

Presentation

6 June 2016
2016 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Chicago, USA
Novel LSD1/HDAC inhibitor 4SC-202 shows in a mouse model that it is an effective combination partner for checkpoint inhibitors

Poster

21 March 2016
3rd Immunotherapy of Cancer Conference
Munich, Germany
A novel LSD1/HDAC inhibitor 4SC-202 inhibits immunosuppression and enhances immunogenicity of tumor cells in vitro and modifies tumor microenvironment in vivo

Poster

8 November 2015
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Boston, USA
The small molecule inhibitor 4SC-202 controls aberrant HH signaling in cancer

Poster

2 June 2014
2014 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Chicago, USA
First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study)

Poster

February 2014
Molecular Medicine Tri-Conference, Cancer Stem Cell Symposium
San Francisco, USA
Targeting cancer stem cells with 4SC-202 – an epigenetic WNT and HH inhibitor

Presentation

February 2014
Keystone Symposia Stem Cells and Cancer
Banff, Canada
4SC-202 – a novel epigenetic modulator to target cancer stem cells

Poster

November 2013
GTC 3rd Cancer Epigenetics Conference
San Francisco, USA
4SC-202 – A Novel Epigenetic Modulator to Target Cancer Stem Cells

Presentation

8 – 9 November 2012
2nd Cancer Epigenetics Conference
Boston, USA
4SC-202 – A Novel Epigenetic Modulator to Target Cancer Stem Cells

Presentation

16 – 19 November 2010
22nd EORTC-NCI-AACR Symposium
Berlin, Germany
Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor

Poster

Share this page:

Follow us on: